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Brief summary: Epidemiological data and modelling suggest a continuing HCV 
epidemic among HIV-diagnosed MSM in the UK driven by high-risk individuals, 
despite high treatment rates. Substantial reductions in HCV transmission could be 
achieved through scale-up of DAA treatments and a behavioural intervention. 
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ABSTRACT 
Background: We report on the hepatitis C virus(HCV) epidemic among HIV-positive 
men who have sex with men(MSM) in the UK and model its trajectory with or 
without scaled-up HCV direct-acting antivirals(DAAs). 
Methods: A dynamic HCV transmission model among HIV-diagnosed MSM in the UK 
was calibrated to HCV prevalence(Ab+ or RNA+), incidence, and treatment from 
2004-2011 among HIV-diagnosed MSM in the UK collaborative HIV cohort(UK CHIC). 
The epidemic was projected with: current or scaled-up HCV treatment, with or 
without a 20% behavioral risk reduction. 
Results: HCV prevalence among HIV-positive MSM in UK CHIC increased from 7.3% in 
2004 to 9.9% in 2011, whereas primary incidence was flat(1.02-1.38 per 100 person-
years). Over the next decade, modelling suggests 94% of infections are attributable 
to high-risk individuals, comprising 7% of the population. Without treatment, HCV 
chronic prevalence could have been 38% higher in 2015(11.9% vs 8.6%). With 
current treatment and SVR rates(status quo), chronic prevalence is likely to increase 
to 11% by 2025, but stabilize with DAA introduction in 2015. With DAAs scale-up to 
80% within one year of diagnosis (regardless of disease stage), 20%/yr thereafter, 
chronic prevalence could reduce by 71% (to 3.2%) compared to status quo in 2025. 
With additional behavioural interventions, chronic prevalence could reduce further 
to <2.5% by 2025.  
Conclusions: Epidemiological data and modelling suggest a continuing HCV epidemic 
among HIV-diagnosed MSM in the UK driven by high-risk individuals, despite high 
treatment rates. Substantial reductions in HCV transmission could be achieved 
through scale-up of DAAs and moderately effective behavioural interventions. 
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Abbreviations: HCV, hepatitis c virus; HIV, human immunodeficiency virus; MSM, 
men who have sex with men; pegIFN, pegylated interferon; RBV, ribavirin; IFN-free, 
interferon free; DAA, direct acting antiviral; UK CHIC, UK Collaborative HIV Cohort 
 
INTRODUCTION 
 
An epidemic of hepatitis C virus (HCV) amongst HIV-positive men who have sex with 
men (MSM)[1, 2] has been documented in cities in Europe, Australia, and the US, 
but with little evidence of transmission amongst HIV-negative MSM[3, 4]. One of 
the key hubs of this epidemic is London[2]. However, the state and future of the UK 
epidemic is uncertain with reported incidence based on case notifications instead of 
longitudinal cohort trends[5, 6].  
 
Modeling indicates HCV antiviral treatment for those at risk of transmission such as 
people who inject drugs (PWID) could have a primary prevention benefit[7-10]. HIV-
positive MSM may be the ideal population to assess HCV treatment as prevention 
(particularly with interferon-free direct-acting antiviral therapy (IFN-free DAAs), 
which are highly effective in this population[11, 12]), because most patients are 
linked to care, frequently HCV tested, and the absolute numbers of HCV-HIV co-
infected MSM are small. However, high reinfection rates (8-15 per 100 person-
years(/100py)[13-15]) among HIV-positive MSM might limit the prevention benefits 
of HCV treatment. 
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To explore the potential impact of new treatments and other interventions on this 
epidemic, we took advantage of detailed available UK data and developed a 
dynamic model of HCV transmission among HIV-positive MSM in the UK, in order to 
assess the epidemic trajectory and project the impact of scaled-up HCV treatment 
as prevention.  
 
 
METHODS 
Epidemiological data analysis 
The UK Collaborative HIV Cohort (UK CHIC) study is an ongoing observational study 
collecting clinical data from 16 HIV treatment centres across the UK[16].  Between 
9/2012-9/2013, additional data were collected on HCV treatment from 11 
participating centres. Individuals were included in the analysis if they had ever 
attended one of the 11 centres since 2004, had an HCV antibody (anti-HCV) or RNA 
test during follow-up, and were recorded as having acquired HIV through sex 
between men.   
 
Cumulative HCV prevalence was calculated yearly as the number of men who had 
ever had a positive anti-HCV or HCV-RNA test by the end of that year as a proportion 
of all those who had been tested by that time.  Incident infection was assessed 
among individuals with a negative anti-HCV test and either negative or missing HCV-
RNA test after 1/1/2004 and at least one further test for anti-HCV or HCV-RNA. 
Individuals were followed-up until a positive anti-HCV or HCV-RNA test or their last 
date seen at a UK CHIC centre. The incidence rate was calculated by dividing the 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
6 
 
total number of incident infections (any positive anti-HCV or HCV-RNA test) by the 
total number of person years of follow-up.  Receipt of HCV treatment (interferon 
(pegylated or non-pegylated) with or without ribavirin, telaprevir, or boceprevir) was 
assessed among all men who had ever received a positive HCV-RNA test.   
 
Mathematical model 
We developed a dynamic, deterministic model of HCV transmission, progression, and 
treatment among diagnosed HIV-positive MSM (Figure 1). Individuals enter at HIV 
diagnosis, a small proportion with existing HCV coinfection. As the model is dynamic, an 
individual’s risk of acquiring HCV is related to background HCV prevalence and their risk 
behavior. The model tracks HCV disease progression and is stratified by HCV diagnosis 
status, treatment history, and transmission risk (high/low, based on factors associated 
with high-risk of HCV acquisition among MSM such as injecting drug use and 
methamphetamine use[17, 18]). We assume MSM who inject do so with other MSM, 
based on phylogenetic evidence indicating HCV MSM strains are clustered separately 
from PWID[19]. For our baseline analysis, we assume HCV uninfected HIV-diagnosed 
MSM are only at risk of HCV acquisition from HIV-diagnosed MSM because of the low 
HCV prevalence among HIV-negative MSM and HIV-positive undiagnosed MSM, 
proportional mixing between risk groups, and movement between high/low risk.  
 
Model parameterization and calibration  
The model was calibrated to annual UK CHIC data on HCV incidence, prevalence (Ab+ 
or RNA+) and proportion ever treated among diagnosed HIV-positive MSM in the UK 
from 2004-2011, and parameterized by data among HIV-diagnosed MSM in the UK 
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(list of parameters in Supplementary Table S1). The model was also calibrated to 
estimated HCV reinfection incidence among MSM in London (7.8/100py (95%CI 5.8-
10.5) across 2004-2012)[14] and the size of the HIV-diagnosed MSM population in 
2013[20].  Model projections were validated against annual size estimates of the 
HIV-diagnosed MSM population from 2001-2013[20, 21].   
 
Based on UK CHIC data, we model treatment rates (from 2003 onwards) of 46% (95%I 
40-53) and 22% (95%I 20-24) treated within 1 year of an acute and chronic diagnosis, 
respectively. Using these rates and the cumulative proportion ever treated by 2011 
(44%), the model estimates an annual treatment rate after the first year of diagnosis of 
6.8% (95%I 3.8-9.9%).  SVR rates for IFN-based therapy among HIV-infected individuals 
came from a published meta-analysis[22]; we assume 90% SVR with DAAs. We 
increased life expectancy from HIV diagnosis over calendar time based on UK data 
reflecting earlier diagnosis/treatment and more effective ART[23], and include excess 
liver-related mortality for MSM coinfected with HCV[24, 25]. 
 
To incorporate parameter uncertainty, 1000 parameter sets were randomly sampled 
from the parameter distributions shown in Table S1.  
 
Intervention scenarios and sensitivity analyses 
We model the UK epidemic from 1996 to 2015, assessing the population attributable 
fraction (PAF) of being high-risk by assessing the relative difference in cumulative 
new infections from 2015 to 2025 if the relative risk between high and low risk is set 
to 1 from 2015 and assuming status quo treatment rates and SVR. We explore the 
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ten-year impact (to 2025) on HCV (Ab+ or RNA+) prevalence, chronic (RNA+) 
prevalence, primary incidence, and numbers treated for the following scenarios 
(summarized in table 3): 
 
 Baseline status quo with IFN/RBV: Continuation of current treatment rates 
and SVR  
 Current treatment rates with DAAs for all: Continuation of current 
treatment rates with DAAs (90% SVR) from 2015 
 DAA scale-up at diagnosis: Scale-up DAA treatment rates to 60%/80%/100% 
treated within 1 year of diagnosis from 2015 
 DAA scale-up to all: Scale-up DAA treatment rates to 80% treated within 1 
year of diagnosis, and 20%/year thereafter from 2015 
 DAA scale-up to all and behavioral intervention: as above and 20% 
behavioral risk reduction from 2015  
 No historical treatment from 1996  
We allow retreatment with DAAs for those who have previously failed IFN-based 
therapies and those who are reinfected.  
 
One-way sensitivity analyses explore the impact of variations in SVR, retreatment 
eligibility, HCV testing rates, risk reductions post-treatment (50% and 100%) or post-
diagnosis (20% for 1 year or until HCV treatment), assortative mixing, seeding of HCV 
from outside the HIV-diagnosed population on the mean chronic HCV prevalence in 
2025 for the DAA scale-up to all scenario (details in supplementary information). 
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RESULTS 
Epidemiological data from UK CHIC 
Nearly all (98%) of MSM in UK CHIC under follow-up in 2011 had been tested for HCV 
(Table 1); the proportion of MSM not known to be infected who were annually HCV-
tested increased from 31% in 2004 to 65% in 2011 (Supplementary Table S2). The 
median number of diagnostic tests until the first positive result per individual was 4 
(IQR: 2,6). 
 
The cumulative HCV prevalence (Ab+ or RNA+) among HIV-positive MSM increased 
from 7.26% in 2004 to 9.86% in 2011 (Table 1).  A total of 11,386 MSM, who were 
initially HCV uninfected and who had at least one further test during median 5 years 
follow-up, were included in the incidence analysis, contributing 54,619 person-years 
of follow-up. Incidence rates from 2004 to 2011 were relatively flat, varying from 
1.02 to 1.38 per 100 person-years of follow-up (Table 2).  
 
A total of 1,403 MSM had ever received a positive RNA result and were considered 
eligible for HCV treatment.  Of these, 36 individuals were excluded as their 
treatment dates were prior to their first positive HCV tests. Therefore, a total of 
1367 MSM were eligible for inclusion in this analysis. Overall, 586/1367 (43%) were 
ever treated, the majority (60%) of treatments occurring within one year of diagnosis 
(Supplementary tables S3, S4).  
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Modelling projections 
The model fits closely matched the number of HIV diagnosed MSM from 2000-2013 
(Figure 2a) and HCV prevalence (Ab+ or RNA+) from 2004-2011 (Figure 2b). The 
projected HCV incidence (1.47/100py) was towards the upper bounds of the UK CHIC 
data (Figure 2c), and projected reinfection incidence (mean 7.8/100py for 2004-
2012) was consistent with UK data[14]. In 2015, the modelled reinfection incidence 
ranged from 4-7 fold that of the primary incidence.   
 
Population attributable fractions 
The model fits estimate a high-risk population size of 7% (2.5%-97.5% Interval(95%I) 
3-14%), consistent with the estimated proportion of HIV-positive MSM in the UK 
reporting injecting drug use or methamphetamine use in the previous 4 weeks[26]. 
These high-risk individuals contribute over one-third of prevalent (37%, 95%I 21-
64%) and incident (36%, 95%I 13-78) infections in 2015. Over the next decade, 94% 
(95%I 91-97) of infections are attributable to high-risk individuals.  
 
Projections of intervention impact to 2025 
Treatment with IFN/RBV  
If HCV treatment and SVR rates remain unchanged, the model predicts steadily 
increasing anti-HCV prevalence, and increasing chronic(RNA+) prevalence from 8.6% 
(95%CI 8.1-9.1) in 2015 to 11% (95%I 9.9-12.1%) in 2025 (Figure 3a,b). Due to the 
expanding epidemic, status quo treatment rates results in greater treatments 
required yearly (Figure 4). In contrast, incidence will remain relatively flat, at 
1.5/100py (95%CI 1.4-1.7) in 2025 (Figure 3c). However, if there was no treatment, 
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chronic prevalence would have been over one-third (38%) higher in 2015 (11.9%, 
95%I 11.1-12.6), and 17.4% (95%I 15.8-18.6) in 2025 (Figure 3b). Similarly, incidence 
would have been 24% higher (1.8/100py, 95%I 1.6-2).  
 
Treatment with DAAs 
If DAAs are provided from 2015 at current treatment rates, chronic prevalence will 
remain virtually unchanged over the next decade (8%, 95%I 7.4-8.6 in 2025), but 
could be a relative 27% lower in 2025 than if IFN/RBV is used (Figure 3b). Modest 
reductions in HCV incidence would be achieved (1.3/100py, 95%I 1.2-1.4 in 2025) 
(Figure 3c).  
 
Treatment scale-up with DAAs 
Substantial reductions in chronic prevalence can be achieved through scale-up of 
DAAs (Figure 3b). If 60%, 80%, or 100% of recently diagnosed (<1 year) individuals 
are treated the year of diagnosis (compared to 46% at baseline) but no change in 
treatment rates for non-recent diagnoses (>1 year), HCV RNA prevalence in 2025 
could decrease to 7.4% (95%I 6.7-8.1), 6.2% (95%I 5.6-7), or 5.0% (95%I 4.4-6), 
respectively (a 33%, 44%, or 55% relative reduction compared to baseline, 
respectively). Similarly, incidence in 2025 could reduce relatively by 15%, 25%, and 
36% compared to baseline, respectively. These treatment increases result in 15%, 
30%, and 41% greater numbers treated for the first year, respectively, but the 
annual numbers treated drop below the status quo scenario by 2022 (Figure 4).  
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More impact is achieved if treatment is scaled-up among those with recent (<1 year) 
and non-recent (>1 year) diagnoses.  If 80% of recent diagnoses and 20%/yr of non-
recent diagnoses are treated (compared to 46%/7% for recent/nonrecent at 
baseline), RNA prevalence could reduce to 3.2% (95%I 2.8-4.1) by 2025 (71% lower 
than 2025 baseline), and incidence could reduce to 0.7/100py (95%I 0.6-1) (56% 
lower than 2025 baseline).   Treatment numbers double the first year, but drop 
quickly, approaching the status quo scenario by 2022 (Figure 4).  
 
If, DAA scale-up (80% <1 year from diagnosis and 20%/yr thereafter) is combined 
with a behavioral intervention that reduces transmission risk by 20% from 2015, HCV 
incidence decreases by 20% within 1 year to 1.2/100py (95%I 1.1-1.3), and to 
0.4/100py (95%I 0.3-0.7) by 2025 (Figure 3c). This combined prevention intervention 
reduces chronic prevalence to 2.4% (95%I 2.1-3.3%) by 2025 (Figure 3b) and lowers 
the annual number of treatments (Figure 4).     
 
Sensitivity analysis 
 
Across our sensitivity analyses, all scenarios predict a chronic RNA prevalence of <4% 
in 2025 with DAA scale-up to all (compared to 3.2% for base-case). Less impact (35% 
relative reduction in chronic prevalence at 2025 compared to base-case) is achieved 
with no retreatment because high treatment rates are not sustainable due to many 
MSM already being treated. Although greater impact occurs if risk reductions occur 
post-treatment from 2015 (20% greater impact if risk is reduced by 100%) the effect 
is limited as retreatment of reinfections is high. Little additional impact (<3% relative 
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difference) is achieved with a short term (<1 year) 20% reduction in risk behavior 
after diagnosis; more substantial impact by 2025 occurs with a sustained behavioral 
intervention targeting all MSM (chronic RNA 2.4% in 2025) than a short-term 
intervention targeting those post-diagnosis (chronic RNA 3.1% in 2025). Little 
difference (<15% relative difference) is seen with varied SVR, scaled-up diagnosis, 
partial assortative mixing of high-risk, or if HCV infections are seeded into the 
population (Supplementary figure S1).  
 
 
DISCUSSION 
 
HCV prevalence (Ab+ or RNA+) among HIV-diagnosed MSM in the UK CHIC study is 
projected to increase under current treatment rates from 9.9% in 2011 to 11% by 
2025. We estimate that a small high-risk group (<10%) contributes over 90% of HCV 
infections over the next decade.  In order to substantially reduce chronic prevalence 
(<3%), treatment scale-up amongst all diagnosed individuals is required, with 
behavior change interventions necessary to achieve immediate reductions in HCV 
incidence. The scaled-up rates we examine translate to a maximum of double the 
numbers of HIV-positive MSM treated (700/year in the UK) compared to the status 
quo initially, but these numbers drop below status quo levels by 2022 due to 
prevention benefits.  
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Comparison with other studies/Limitations 
To our knowledge, this is the first study to model the HCV epidemic among HIV-
infected MSM. Though our analysis is UK-focused, other settings have similar 
incidence [27-29]. The stable incidence levels found in UK are similar to 
Amsterdam[29] and USA[30], whereas increasing incidence is reported in 
Switzerland[28]. Given its large size and wide representation of UK clinics, UK CHIC is 
broadly representative of people living with HIV and attending for HIV care in the 
UK. Our UK CHIC estimate is slightly higher than reported previously in the UK[5, 6] 
based on case notification data but also slightly lower than projected by our 
modelling. Two potential sources of under-estimation by UK CHIC data could be due 
to incident infections without a previous negative test being excluded, or follow-up 
time being over-estimated for patients that cycle in/out of UK CHIC clinics,  which if 
occurring among higher-risk individuals, could lead to true incidence being 
underestimated. On the other hand, it is possible those tested are at higher-risk of 
infection, which would overestimate true incidence.  
 
The model projections are limited by several sources of uncertainty which remain 
even after the uncertainty analyses. First, we model HCV transmission among HIV-
diagnosed MSM only, although we include inflow of HIV/HCV coinfected individuals 
at HIV diagnosis which are unaffected by our interventions. It is possible 
interventions for HIV-diagnosed MSM would also reduce incidence among HIV-
undiagnosed MSM, in which case we would expect more impact than shown. 
Additionally, our sensitivity analysis suggests seeding of HCV infections from HIV 
undiagnosed or HIV-negative individuals would have minimal impact. It is unclear 
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whether the higher HCV prevalence among HIV-diagnosed MSM compared to HIV 
undiagnosed or HIV-negative individuals is related to changing risk behavior upon 
HIV diagnosis, a longer time at risk, or individuals with elevated risk behaviors 
compared to the general MSM population acquiring both HIV and HCV. 
 
Second, there are limited data defining HCV-related risk behaviours among HIV-
positive MSM, and therefore we allowed details of the high-risk population (size, 
relative risk, time at risk) to vary as part of the model calibration. Additionally, 
although we include behavioural heterogeneity, we do not explicitly model the 
transmission network. It is possible that highly connected super-spreaders are 
responsible for many HCV transmission events and should be targeted for 
prevention. Similarly, we neglect international migration/travel due to a lack of 
available data, movement which could seed infections and limit the impact of 
localized interventions. Better epidemiological data on these factors is critical to 
strengthening the model predictions.    
 
Third, we explore a hypothetical 20% effective behavioral risk intervention, which 
was not based on a proven intervention in this population. Unfortunately, there is no 
empirical evidence that this level of HCV risk reduction is achievable. A Cochrane 
review found evidence for the effectiveness of behavior change interventions to 
reduce unprotected anal sex among MSM such as counseling, social and behavioral 
support, reporting an overall reduction by 27% (95%CI 15-37%)[31]. These 
interventions, though primarily aimed at reducing HIV risk, could be effective for 
HCV as well. Additionally, among people who inject drugs, opiate substitution 
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therapy and high coverage needle and syringe programmes can reduce an 
individual’s risk of HCV acquisition by 50% alone, or 80% in combination[32], but it is 
unclear how applicable these interventions are to the HCV epidemic among MSM. It 
is possible both sexual and injecting-related interventions could play an important 
role, such as prevention messaging training among sexual health/HIV clinic staff and 
the distribution of safe chemsex kits. One UK clinic is currently examining the impact 
of club drug behavior change intervention among MSM, but the impact is uncertain 
at present.  
 
Fourth, we examine DAA scale-up for both acute and chronic infection as 
European[33] and US[34] guidelines recommend DAA therapy regardless of liver 
disease stage for HIV/HCV coinfected individuals. However, if DAAs are prioritized or 
restricted to those with more advanced liver disease then the prevention impact 
could be less than we predict. As such, the individual and population benefits 
achievable strongly support not restricting access to DAA therapy among HIV/HCV 
coinfected MSM. Nevertheless, even if IFN-free DAA therapy is prioritized to those 
with advanced liver disease, it is possible IFN-based treatment uptake among those 
with less advanced disease will remain high given historically high rates of uptake 
among HIV-coinfected MSM.  
 
Conclusion 
We report a continuing epidemic among HIV-diagnosed MSM in the UK, despite high 
rates of treatment, which is largely attributable to a high-risk population. Substantial 
reductions in HCV transmission within a decade could be achieved through rapid 
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DAA scale-up and moderately successful behavioural interventions. This impact 
could be achieved despite reinfection rates which are roughly five-fold higher than 
primary incidence, because the shortening and ease of delivery of new IFN-free 
DAAs enables scale-up with existing infrastructure.  Given their importance in driving 
ongoing HCV transmission, there is a need to develop effective interventions to 
address high-risk behaviours associated with injecting and other drug use among 
MSM.  
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FIGURE LEGENDS 
 
Figure 1. Mathematical model schematic. The model is also stratified by treatment 
naïve, IFN experienced, DAA experienced, and low/high risk states. HIV and non-HIV 
death occurs from all states. MSM: men who have sex with men; HCV: hepatitis C 
virus 
 
Figure 2. Model fits to epidemiological data from the UK. (A) Number of HIV-
diagnosed MSM, (B) HCV prevalence (Ab+ or RNA+) among diagnosed HIV-positive 
MSM, (C) HCV primary incidence among diagnosed HIV-positive MSM in the UK. 
Solid lines show the mean value of all 1000 simulations, dashed lines show the 2.5% 
and 97.5% range of the projections. Black diamonds show data from Public Health 
England (in Fig 2A, model calibrated to 2013 value, other values shown for 
validation) and UK CHIC (Fig 2B and 2C, model calibrated against all data points).  
 
Figure 3. Model projections (mean value of 1000 simulations shown) with various 
treatment scenarios (A) HCV prevalence (Ab+ or RNA+) among HIV-positive MSM in 
the UK, (B) HCV chronic (RNA) prevalence among HIV-positive MSM in the UK, (C) 
HCV primary incidence among HIV-positive MSM in the UK 
 
Figure 4. Model projections of the mean number of HCV treatments for HIV-
infected MSM in the UK for different treatment scenarios.  
 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
26 
 
 Table 1.  Cumulative prevalence (Ab+ or RNA+) of hepatitis C among HIV-positive 
MSM in UK CHIC. UK CHIC: Collaborative HIV Cohort; MSM: men who have sex with 
men; HCV: hepatitis C virus 
 
Year Total 
number of 
MSM 
under 
follow-up 
in that 
year in UK 
CHIC 
Total 
number of 
MSM under 
follow-up in 
that year 
with a 
reported 
test by end 
of year 
% with a 
HCV test 
reported 
by end of 
that year 
Cumulative 
number HCV 
positive (Ab+ 
or RNA+) 
Cumulative 
HCV 
prevalence  
(Ab+ or RNA+) 
(%) 
2004 11012 6774 61.51 492 7.26 
2005 11765 8398 71.38 641 7.63 
2006 12335 9550 77.42 752 7.87 
2007 12895 10808 83.82 896 8.29 
2008 13262 11799 88.97 1049 8.89 
2009 13693 12607 92.07 1195 9.48 
2010 14147 13369 94.50 1293 9.67 
2011 13101 12789 97.62 1261 9.86 
Ever 17574 16533 94.08 1673 10.12 
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Table 2. Incidence of hepatitis C among HIV-positive MSM in UK CHIC. UK CHIC: 
Collaborative HIV Cohort; MSM: men who have sex with men; HCV: hepatitis C virus; 
CI: confidence interval 
 
Year Person years of 
follow-up of those 
HCV Ab negative 
New infections Incidence per 100 
person years of 
follow-up (95% CI) 
2004 1454 15 1.03 (0.58-1.70) 
2005 4179 51 1.22 (0.91-1.60) 
2006 6076 62 1.02 (0.78-1.31) 
2007 7484 103 1.38 (1.12-1.67) 
2008 8752 106 1.21 (0.99-1.46) 
2009 9405 111 1.18 (0.97-1.42) 
2010 9782 101 1.03 (0.84-1.25) 
2011 7487 80 1.07 (0.85-1.33) 
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Table 3. Mathematical modeling scenarios. IFN/RBV:  pegylated interferon+ribavirin, 
DAA: direct acting antivirals, SVR: sustained viral response 
 
Model Scenario SVR <1 year 
from HCV 
infection 
(sampled 
range) 
SVR >1 
year after 
acute 
infection 
(sampled 
range) 
Proportion 
treated 
after acute 
diagnosis  
(sampled 
range) 
Proportion 
treated the 
first year 
after chronic 
diagnosis 
(sampled 
range) 
Proportion 
treated 
thereafter  
Behavioral 
interventi
on 
Baseline status quo 
with IFN/RBV 
80% (70-90%) 30% (25-
35%) 
46% (40-
53%) 
22% (20-
24%) 
mean 5.9% 
(2.5%-
97.5% fits 
3.5-10) 
no 
Current treatment 
with DAA for all 
90% 90% As in 
baseline 
As in 
baseline 
As in 
baseline 
no 
DAA scale-up at 
diagnosis 
90% 90% 60/80/100% 60/80/100% As in 
baseline 
no 
DAA scale up to all 90% 90% 80% 80% 20% no 
DAA scale up to all 
and behavioral 
intervention 
90% 90% 80% 80% 20% 20% 
reduction 
in risk for 
all 
No historical 
treatment 
N/A N/A 0% (No 
treatment 
from 1996) 
0% (No 
treatment 
from 1996) 
0% (No 
treatment 
from 1996) 
no 
 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
29 
 
 
 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
30 
 
 
 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
31 
 
 
 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
32 
 
 
 
 at Im
perial College London on M
arch 2, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
